318 related articles for article (PubMed ID: 26984210)
21. A randomized phase 1 pharmacokinetic trial comparing the potential biosimilar PF-05280014 with trastuzumab in healthy volunteers (REFLECTIONS B327-01).
Yin D; Barker KB; Li R; Meng X; Reich SD; Ricart AD; Rudin D; Taylor CT; Zacharchuk CM; Hansson AG
Br J Clin Pharmacol; 2014 Dec; 78(6):1281-90. PubMed ID: 25041377
[TBL] [Abstract][Full Text] [Related]
22. A Randomized, Double-Blind, Parallel-Controlled Phase I Study Comparing the Pharmacokinetics, Safety, and Immunogenicity of SCT510 to Bevacizumab (Avastin
Wu J; Wu G; Xie L; Lv D; Xu C; Zhou H; Wu L; Zhang J; Shentu J
Drugs R D; 2023 Jun; 23(2):175-183. PubMed ID: 37247166
[TBL] [Abstract][Full Text] [Related]
23. Bioequivalence, safety and immunogenicity of BI 695501, an adalimumab biosimilar candidate, compared with the reference biologic in a randomized, double-blind, active comparator phase I clinical study (VOLTAIRE®-PK) in healthy subjects.
Wynne C; Altendorfer M; Sonderegger I; Gheyle L; Ellis-Pegler R; Buschke S; Lang B; Assudani D; Athalye S; Czeloth N
Expert Opin Investig Drugs; 2016 Dec; 25(12):1361-1370. PubMed ID: 27813422
[TBL] [Abstract][Full Text] [Related]
24. Pharmacokinetics and safety of candidate tocilizumab biosimilar CT-P47 versus reference tocilizumab: a randomized, double-blind, single-dose phase I study.
Yu KS; Kim B; Shin D; Park MK; Hwang JG; Kim MG; Chung H; Ghim J; Chung JY; Smolen JS; Burmester GR; Kim S; Bae Y; Jeon D; Yoo J; Yang G; Bae J; Keystone E
Expert Opin Investig Drugs; 2023 May; 32(5):429-439. PubMed ID: 37231670
[TBL] [Abstract][Full Text] [Related]
25. PF-06439535 (a Bevacizumab Biosimilar) Compared with Reference Bevacizumab (Avastin
Reinmuth N; Bryl M; Bondarenko I; Syrigos K; Vladimirov V; Zereu M; Bair AH; Hilton F; Liau K; Kasahara K
BioDrugs; 2019 Oct; 33(5):555-570. PubMed ID: 31338773
[TBL] [Abstract][Full Text] [Related]
26. HLX11, a Proposed Pertuzumab Biosimilar: Pharmacokinetics, Immunogenicity, and Safety Profiles Compared to Three Reference Biologic Products (US-, EU-, and CN-Approved Pertuzumab) Administered to Healthy Male Subjects.
Yang J; Lin L; Long Q; Zhang Q; Sun G; Zhou L; Wang Q; Zhu J; Li F; Hu W
BioDrugs; 2022 May; 36(3):393-409. PubMed ID: 35594017
[TBL] [Abstract][Full Text] [Related]
27. A randomized phase I comparative pharmacokinetic study comparing SB5 with reference adalimumab in healthy volunteers.
Shin D; Lee Y; Kim H; Körnicke T; Fuhr R
J Clin Pharm Ther; 2017 Dec; 42(6):672-678. PubMed ID: 28675520
[TBL] [Abstract][Full Text] [Related]
28. Pharmacokinetics, Tolerability, Safety, and Immunogenicity of LY01008 and Bevacizumab (Avastin®) in Healthy Chinese Subjects.
Xie L; Zhu Y; Liang Z; Zhao Y; Zhou S; Chen J; Zhang H; Ding S; Wang L; Shao F
Eur J Drug Metab Pharmacokinet; 2022 May; 47(3):309-317. PubMed ID: 35112328
[TBL] [Abstract][Full Text] [Related]
29. Comparison of pharmacokinetics, pharmacodynamics, safety, and immunogenicity of teriparatide biosimilar with EU- and US-approved teriparatide reference products in healthy men and postmenopausal women.
Fenwick S; Vekariya V; Patel R; Hajela P; Modi K; Kale P; Nath A
Osteoporos Int; 2023 Jan; 34(1):179-188. PubMed ID: 36287230
[TBL] [Abstract][Full Text] [Related]
30. A randomized, double-blind, parallel-group phase I study comparing the pharmacokinetics, safety, and immunogenicity of LY01008, a candidate bevacizumab biosimilar, with its reference product Avastin® in healthy Chinese male subjects.
Zhou R; Yang J; Liu Y; Zhang Q; Lu C; Tang K; Li X; Tang W; Gao E; Wu C; Dou C; Hu W
Expert Opin Biol Ther; 2022 Feb; 22(2):263-269. PubMed ID: 34913787
[TBL] [Abstract][Full Text] [Related]
31. Pharmacokinetic equivalence, comparable safety, and immunogenicity of an adalimumab biosimilar product (M923) to Humira in healthy subjects.
Hillson J; Mant T; Rosano M; Huntenburg C; Alai-Safar M; Darne S; Palmer D; Pavlova BG; Doralt J; Reeve R; Goel N; Weilert D; Rhyne PW; Chance K; Caminis J; Roach J; Ganguly T
Pharmacol Res Perspect; 2018 Feb; 6(1):. PubMed ID: 29417761
[TBL] [Abstract][Full Text] [Related]
32. Pharmacokinetic bioequivalence, safety, and immunogenicity of GB222, a bevacizumab biosimilar candidate, and bevacizumab in Chinese healthy males: a randomized clinical trial.
Dong W; Chen M; Niu S; Wang B; Xia L; Wang J; Shen T; Wang Q; Lv J; Liu G; Fan H; Xie Z; Xie F; An Y; Zheng Q; Rao H; Song H; Fang Y
Expert Opin Biol Ther; 2022 Feb; 22(2):253-262. PubMed ID: 34236011
[TBL] [Abstract][Full Text] [Related]
33. PF-06881894, a Proposed Biosimilar to Pegfilgrastim, Versus US-Licensed and EU-Approved Pegfilgrastim Reference Products (Neulasta
Moosavi S; Borema T; Ewesuedo R; Harris S; Levy J; May TB; Summers M; Thomas JS; Zhang J; Yao HM
Adv Ther; 2020 Jul; 37(7):3370-3391. PubMed ID: 32524499
[TBL] [Abstract][Full Text] [Related]
34. Comparison of the pharmacokinetics, safety, and immunogenicity of MSB11022, a biosimilar of adalimumab, with Humira(®) in healthy subjects.
Hyland E; Mant T; Vlachos P; Attkins N; Ullmann M; Roy S; Wagner V
Br J Clin Pharmacol; 2016 Oct; 82(4):983-93. PubMed ID: 27285856
[TBL] [Abstract][Full Text] [Related]
35. Population pharmacokinetic modeling of PF-06439535 (a bevacizumab biosimilar) and reference bevacizumab (Avastin
Li CSW; Sweeney K; Cronenberger C
Cancer Chemother Pharmacol; 2020 Mar; 85(3):487-499. PubMed ID: 31768697
[TBL] [Abstract][Full Text] [Related]
36. A Randomized, Phase I Pharmacokinetic Study Comparing SB2 and Infliximab Reference Product (Remicade(®)) in Healthy Subjects.
Shin D; Kim Y; Kim YS; Körnicke T; Fuhr R
BioDrugs; 2015 Dec; 29(6):381-8. PubMed ID: 26577771
[TBL] [Abstract][Full Text] [Related]
37. Pharmacokinetics, safety, tolerability and immunogenicity of FKB327, a new biosimilar medicine of adalimumab/Humira, in healthy subjects.
Puri A; Niewiarowski A; Arai Y; Nomura H; Baird M; Dalrymple I; Warrington S; Boyce M
Br J Clin Pharmacol; 2017 Jul; 83(7):1405-1415. PubMed ID: 28133772
[TBL] [Abstract][Full Text] [Related]
38. A Randomized Phase I Pharmacokinetic Study Comparing Biosimilar Candidate SB3 and Trastuzumab in Healthy Male Subjects.
Pivot X; Curtit E; Lee YJ; Golor G; Gauliard A; Shin D; Kim Y; Kim H; Fuhr R
Clin Ther; 2016 Jul; 38(7):1665-1673.e3. PubMed ID: 27368117
[TBL] [Abstract][Full Text] [Related]
39. Pharmacokinetic Similarity of ABP 710, a Proposed Biosimilar to Infliximab: Results From a Randomized, Single-Blind, Single-Dose, Parallel-Group Study in Healthy Subjects.
Chow V; Oh M; Gessner MA; Fanjiang G
Clin Pharmacol Drug Dev; 2020 Feb; 9(2):246-255. PubMed ID: 31628783
[TBL] [Abstract][Full Text] [Related]
40. Pharmacokinetic Similarity and Comparative Pharmacodynamics, Safety, Efficacy, and Immunogenicity of DRL_RI Versus Reference Rituximab in Biologics-Naïve Patients with Moderate-to-Severe Rheumatoid Arthritis: A Double-Blind, Randomized, Three-Arm Study.
Haridas VM; Katta R; Nalawade A; Kharkar S; Zhdan V; Garmish O; Lopez-Lazaro L; Batra SS; Kankanwadi S
BioDrugs; 2020 Apr; 34(2):183-196. PubMed ID: 32052313
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]